Nisa Investment Advisors’s Tenaya Therapeutics TNYA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.66K Hold
2,252
﹤0.01% 2782
2026
Q1
$1.56K Hold
2,252
﹤0.01% 2662
2025
Q4
$1.6K Hold
2,252
﹤0.01% 2644
2025
Q3
$3.65K Hold
2,252
﹤0.01% 2506
2025
Q2
$1.38K Buy
2,252
+2,102
+1,401% +$1.07K ﹤0.01% 2683
2025
Q1
$86 Sell
150
-4,515
-97% -$4.45K ﹤0.01% 2969
2024
Q4
$6.67K Buy
4,665
+2,802
+150% +$6.28K ﹤0.01% 2217
2024
Q3
$3.6K Sell
1,863
-49
-3% -$138 ﹤0.01% 2282
2024
Q2
$5.93K Buy
1,912
+972
+103% +$4.01K ﹤0.01% 2249
2024
Q1
$4.92K Buy
940
+40
+4% +$191 ﹤0.01% 2121
2023
Q4
$2.92K Sell
900
-2,930
-77% -$6.32K ﹤0.01% 2160
2023
Q3
$9.77K Buy
3,830
+1,870
+95% +$7.83K ﹤0.01% 2181
2023
Q2
$11.5K Buy
1,960
+900
+85% +$5.23K ﹤0.01% 2234
2023
Q1
$3K Sell
1,060
-4,090
-79% -$11.5K ﹤0.01% 2296
2022
Q4
$10K Buy
5,150
+1,050
+26% +$2.56K ﹤0.01% 2210
2022
Q3
$11K Buy
+4,100
New +$19.1K ﹤0.01% 2174

Other funds holding TNYA

Nisa Investment Advisors's TNYA Position: Q2 2026 in Review

Nisa Investment Advisors held its Tenaya Therapeutics (TNYA) position steady in Q2 2026 at 2,252 shares worth $1.66K. The position accounts for ﹤0.01% of the portfolio, ranked #2782.

Nisa Investment Advisors first reported a position in TNYA in Q3 2022 and has held it in 16 quarters since. The position peaked at $11.5K in Q2 2023. 41 funds tracked by Wall St. Rank hold TNYA as of Q2 2026.

  • Nisa Investment Advisors held 2,252 shares of Tenaya Therapeutics worth $1.66K as of Q2 2026.
  • Nisa Investment Advisors left its Tenaya Therapeutics share count unchanged in Q2 2026.
  • Tenaya Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2782 holding.
  • Nisa Investment Advisors first reported a position in Tenaya Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • Nisa Investment Advisors's Tenaya Therapeutics position peaked at $11.5K in Q2 2023.
  • 41 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.